Back to top

Image: Bigstock

Trevi Therapeutics' (TRVI) Shares March Higher, Can It Continue?

Read MoreHide Full Article

As of late, it has definitely been a great time to be an investor in Trevi Therapeutics, Inc. (TRVI - Free Report) . The stock has moved higher by 6.5% in the past month, while it is also above its 20 day SMA too. This combination of strong price performance and favorable technical could suggest that the stock may be on the right path.

We certainly think that this might be the case, particularly if you consider TRVI’s recent earnings estimate revision activity. From this look, the company’s future is quite favorable; as TRVI has earned itself a Zacks Rank #2 (Buy), meaning that its recent run may continue for a bit longer, and that this isn’t the top for the in-focus company. You can see the complete list of today’s Zacks #1 Rank stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Trevi Therapeutics, Inc. (TRVI) - free report >>

Published in